Critics of the industry already challenge (wrongly, in my view) that new medicines offer little advantage to older products and may even be less safe.
FORBES: Importance of a Drug's "Risk-Benefit" Profile Eludes Former FDA Commissioner
应用推荐
模块上移
模块下移
不移动